Raloxifene (Evista): Uses, Benefits, and Safety Profile

Raloxifene is a selective estrogen receptor modulator (SERM) with tissue-specific estrogen agonist/antagonist effects.

FDA-Approved Indications

1. Osteoporosis Prevention/Treatment in Postmenopausal Women: Agonist at bone ER → maintains BMD, reduces vertebral fracture risk ~30–50%. No significant effect on non-vertebral/hip fractures.

2. Breast Cancer Risk Reduction: Antagonist at breast ER → reduces invasive ER+ breast cancer incidence by ~50–76% in high-risk postmenopausal women (STAR trial vs. tamoxifen). Not for treatment of existing breast cancer.

Additional Effects

  • Lipids: Lowers total and LDL cholesterol (~10–12%); minimal effect on HDL, triglycerides.
  • Coagulation: No increase in VTE risk vs. placebo in osteoporosis trials, but contraindicated with history of VTE.
  • Endometrium: Neutral (no hyperplasia risk vs. tamoxifen).
  • Hot flashes: May worsen; not indicated for vasomotor symptoms.

Contraindications & Precautions

  • History of VTE (DVT, PE, retinal vein thrombosis)
  • Active or recent major surgery with immobilization
  • Pregnancy (Category X)
  • Severe hepatic impairment
  • Unexplained uterine bleeding

Monitoring

BMD q1–2 years. Clinical breast exams, mammograms per guidelines. No routine endometrial surveillance needed. Counsel on VTE symptoms (calf pain, dyspnea) and stroke signs.

Prescription Medications - Related Articles